U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
 Annual Meeting - EconoTimes)
EAGAN, Minn., March 27, 2017 -- Biothera Pharmaceuticals Inc. announced today that it will present three scientific posters at the American Association for Cancer Research (AACR) Annual Meeting April 1-5 in Washington, D.C. One poster was selected for the late-breaking session that highlights the newest and most exciting research.
Poster Presentations:
| Session Date & Time: | Monday, April 3, 8:00 AM - 12:00 PM Eastern Time | ||||||||||
| Topic Track: | Immunology | ||||||||||
| Session: | Adaptive Immunity to Cancer | ||||||||||
| Presentation Title: | A novel tumor vaccine platform: direct conjugation of antigens to the β-glucan PAMP Imprime PGG enhances antigen presentation and T cell priming | ||||||||||
| Session Location: | Poster Section 29 | ||||||||||
| Poster Board Number: | 22 | ||||||||||
| Abstract #: | 1703 | ||||||||||
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Late-Breaking Research: Immunology | ||
| Presentation Title: | Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies | ||
| Session Location: | Poster Section 35 | ||
| Poster Board Number: | 22 | ||
| Abstract #: | LB-199 |
| Session Date & Time: | Tuesday, April 4, 8:00 AM - 12:00 PM Eastern Time | ||
| Topic Track: | Immunology | ||
| Session: | Inflammation in the Tumor Microenvironment | ||
| Presentation Title: | Imprime PGG, a novel innate immune therapeutic in phase 2 clinical development, induces mobilization of monocytes and focalized recruitment of innate immune cells to tumor sites | ||
| Session Location: | Poster Section 28 | ||
| Poster Board Number: | 1 | ||
| Abstract #: | 3688 |
About Biothera Pharmaceuticals, Inc.
Biothera Pharmaceuticals is a privately held biotechnology company developing Imprime PGG, a Phase 2 cancer immunotherapy that enhances the efficacy of anti-cancer immune response in combination with immune checkpoint inhibitor, tumor-targeting and anti-angiogenesis antibodies. Biothera Pharmaceuticals has clinical research agreements with Merck to evaluate Imprime PGG and KEYTRUDA® in Phase 2 studies in advanced melanoma, metastatic triple negative breast cancer, and head and neck squamous cell cancer. This therapeutic combination also is the focus of a Big Ten Cancer Research Consortium Phase 1b/2 trial in patients with non-small cell lung cancer. Imprime PGG has been well-tolerated and has established proof of concept in trials with more than 400 subjects.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Contact: David Walsh Communications Biothera Pharmaceuticals, Inc. 651-256-4606 [email protected]
